New EU GMP Annex 1 – Implications for QRM application by Alessio Rosati Sterility Assurance Executive Consultant – PQE Group The issues exposed in this article will be discussed in Contamination Control Strategy – Next year’s challenge for Pharma Quality Systems, from new EU GMP Annex 1″ free Webinar by PQE, next March 9th@ 10 […]
Covid-19 vaccines supply chain has become a target for cybersecurity attacks. How real is the threat? by Damiano Peruzzi – PQE Group Abstract In the constantly evolving scenario of Cybercrime, two main aspects reveal an increased urgency of tackling the challenges posed by Cyber Threats. The first is the fast scalability of cyber targets, which […]
The second draft of GMP Annex 1 has been recently released and the issue date for the new revision is finally approaching. The document, a milestone standard for all sterile manufacturers, has been widely revised and extended.
We consider the potential risks for Pharma and MD companies keeping their systems running on obsolete Windows versions and a good strategy to get up to date.
Why MD Cybersecurity is so important? PQE Group – 3/12/2019 The hidden risks of a disruptive innovation. Is Cybersecurity important for Medical Devices? The answer is absolutely yes. But let’s move a bit backwards, to understand the reason why nowadays Cybersecurity has become a main concern for all Medical Devices producers. It’s well renowned that […]
On September 26th, 2019 the CMDh published the notice “Information on nitrosamines for marketing authorisation holders” asking to all Marketing Authorization Holders (MAHs) of human medicinal products containing chemically synthesised active pharmaceutical ingredients to evaluate the risk of the presence of nitrosamine impurities in their products. This includes generics and over-the counter (OTC) products.